1102 related articles for article (PubMed ID: 25283629)
1. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
2. What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of Musashi-1 in gliomas.
Dahlrot RH; Hansen S; Herrstedt J; Schrøder HD; Hjelmborg J; Kristensen BW
J Neurooncol; 2013 Dec; 115(3):453-61. PubMed ID: 24057325
[TBL] [Abstract][Full Text] [Related]
4. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
5. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
[TBL] [Abstract][Full Text] [Related]
7. In vitro neurosphere formation correlates with poor survival in glioma.
C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S
IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962
[TBL] [Abstract][Full Text] [Related]
8. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
[TBL] [Abstract][Full Text] [Related]
9. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.
He J; Liu Y; Zhu T; Zhu J; Dimeco F; Vescovi AL; Heth JA; Muraszko KM; Fan X; Lubman DM
Mol Cell Proteomics; 2012 Jun; 11(6):M111.010744. PubMed ID: 22203689
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic value of JAM-A in gliomas.
Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
[TBL] [Abstract][Full Text] [Related]
11. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival.
Strojnik T; Røsland GV; Sakariassen PO; Kavalar R; Lah T
Surg Neurol; 2007 Aug; 68(2):133-43; discussion 143-4. PubMed ID: 17537489
[TBL] [Abstract][Full Text] [Related]
12. Stem cell markers in gliomas.
Dell'Albani P
Neurochem Res; 2008 Dec; 33(12):2407-15. PubMed ID: 18493853
[TBL] [Abstract][Full Text] [Related]
13. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Shin JH; Lee YS; Hong YK; Kang CS
J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
15. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
Li MW; Niu CS
Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
[TBL] [Abstract][Full Text] [Related]
16. A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
J Neurooncol; 2013 Sep; 114(3):309-17. PubMed ID: 23817809
[TBL] [Abstract][Full Text] [Related]
17. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
[TBL] [Abstract][Full Text] [Related]
18. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
Int J Clin Exp Pathol; 2013; 6(1):31-40. PubMed ID: 23236540
[TBL] [Abstract][Full Text] [Related]
19. Sequential expression of putative stem cell markers in gastric carcinogenesis.
Wang T; Ong CW; Shi J; Srivastava S; Yan B; Cheng CL; Yong WP; Chan SL; Yeoh KG; Iacopetta B; Salto-Tellez M
Br J Cancer; 2011 Aug; 105(5):658-65. PubMed ID: 21829201
[TBL] [Abstract][Full Text] [Related]
20. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]